Kantonsspital St.Gallen


Riana Peischl, Andrea Rubbert Roth & Mira Bartz Batliner

abstract a phase 3, double-blind, multicenter study of evaluate the long-term safety and efficacy of baricitinib in patients with SLE.
type of project clinical studies
status ongoing - follow up
start of project 2020
end of project 2024
study design patients randomized to active treatment, baricitinib 4mg daily or baricitinib 2mg daily, during study JAHZ or JAIA will continue on the same, blinded, dose of baricitinib in study JAIM. patients randomized to placebo during JAHZ or JAIA will be randomized 1:1 to receive baricitinib 4mg or 2mg daily during study JAIM. the treatment period will last up to 156 weeks from enrollment into study JAIM.
responsible person Dr.Prof.Andrea Rubbert-Roth